SEC Company Response from INTROGEN THERAPEUTICS INC (CIK 0001018710) — Sep 30, 2005
INTROGEN THERAPEUTICS INC (CIK 0001018710)
Date: Sept. 30, 2005 · CIK: 0001018710 · Accession: 0000950134-05-018641
AI Filing Summary & Sentiment
File numbers found in text: 000-21291
Referenced dates: August 9, 2005
Letter
Via EDGAR Securities and Exchange Commission Introgen Therapeutics, Inc. Annual Report on Form 10-K for the year ended December 31, 2004 Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 File No. 000-21291
Re:
Dear Ms. Bruckner:
On behalf of Introgen Therapeutics, Inc. (“Introgen” or the “Company”), we hereby inform you that on or before October 7, 2005 Introgen intends to file a further response to comments from the Staff of the Securities and Exchange Commission received by letter dated August 9, 2005 relating to Introgen’s Annual Report on Form 10-K for the year ended December 31, 2004 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2005.
If you have any additional questions or comments, please feel free to contact Chris Ozburn at (512) 338-5414 or me at (512) 338-5420.
Sincerely,
WILSON SONSINI GOODRICH & ROSATI,
Show Raw Text
CORRESP
1
filename1.htm
corresp
September 30, 2005
Via EDGAR
Amy Bruckner
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re:
Introgen Therapeutics, Inc.
Annual Report on Form 10-K for the year ended December 31, 2004
Quarterly Report on Form 10-Q for the quarter ended March 31, 2005
File No. 000-21291
Dear Ms. Bruckner:
On behalf of Introgen Therapeutics, Inc. (“Introgen” or the “Company”), we
hereby inform you that on or before October 7, 2005 Introgen intends to file a further response to
comments from the Staff of the Securities and Exchange Commission received by letter dated August
9, 2005 relating to Introgen’s Annual Report on Form 10-K for the year ended December 31, 2004 and
Quarterly Report on Form 10-Q for the quarter ended March 31, 2005.
If you have any additional questions or comments, please feel free to contact Chris Ozburn at
(512) 338-5414 or me at (512) 338-5420.
Sincerely,
WILSON SONSINI GOODRICH & ROSATI,
Professional Corporation
/s/ ALAN BICKERSTAFF
Alan Bickerstaff
cc:
Jim B. Rosenberg, Securities and Exchange Commission (via EDGAR)
Joel Parker, Securities and Exchange Commission (via EDGAR)
Jim Albrecht, Introgen Therapeutics, Inc. (via facsimile)
Alan Bickerstaff